{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:52:25Z","timestamp":1785369145715,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1F31DA060690-01"],"award-info":[{"award-number":["1F31DA060690-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA029926"],"award-info":[{"award-number":["P30DA029926"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01386-7","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:46:13Z","timestamp":1768286773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u2018It wasn\u2019t to get high; it was just to get by\u2019: experiences of patients who use fentanyl during methadone treatment and opportunities for improving care in Vermont and New Hampshire"],"prefix":"10.1186","volume":"23","author":[{"given":"Jesse S.","family":"Boggis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Marsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri","family":"Bryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy J.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1386_CR1","volume-title":"The synthetic opioid surge in the United States: insights from mortality and seizure data","author":"B Pardo","year":"2019","unstructured":"Pardo B, Caulkins JP, Kilmer B, Pacula RL, Reuter P, Stein BD. The synthetic opioid surge in the United States: insights from mortality and seizure data. Santa Monica: RAND Corporation; 2019."},{"key":"1386_CR2","unstructured":"Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). Final Data Atlanta, GA: US Department of Health and Human Services, CDC; [updated 2025. Available from: https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html."},{"issue":"4","key":"1386_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"issue":"34","key":"1386_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","volume":"70","author":"S Liu","year":"2021","unstructured":"Liu S, O\u2019Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines - 38 states and the district of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136\u201341.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1386_CR5","unstructured":"United States Food & Drug Administration. Information about Medications for Opioid Use Disorder (MOUD) [updated December, 26, 2024. Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medications-opioid-use-disorder-moud."},{"issue":"3","key":"1386_CR6","first-page":"Cd002209","volume":"2009","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochr Datab Syst Rev. 2009;2009(3):Cd002209.","journal-title":"Cochr Datab Syst Rev"},{"issue":"2","key":"1386_CR7","first-page":"Cd002207","volume":"2014","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochr Datab Syst Rev. 2014;2014(2):Cd002207.","journal-title":"Cochr Datab Syst Rev"},{"issue":"22","key":"1386_CR8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2013tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"1386_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatr. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiatr"},{"key":"1386_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000922","author":"NB Varshneya","year":"2021","unstructured":"Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2021. https:\/\/doi.org\/10.1097\/ADM.0000000000000922.","journal-title":"J Addict Med"},{"issue":"2","key":"1386_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dar.13394","volume":"41","author":"D Shearer","year":"2022","unstructured":"Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series. Drug Alcohol Rev. 2022;41(2):444\u20138.","journal-title":"Drug Alcohol Rev"},{"issue":"S2","key":"1386_CR12","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","volume":"112","author":"C Simon","year":"2022","unstructured":"Simon C, Vincent L, Coulter A, Salazar Z, Voyles N, Roberts L, et al. The Methadone Manifesto: treatment experiences and policy recommendations from methadone patient activists. Am J Public Health. 2022;112(S2):S117\u201322.","journal-title":"Am J Public Health"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. \u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1386_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"5","key":"1386_CR15","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O'Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"key":"1386_CR16","unstructured":"Substance Use and Mental Health Services Administration. Methadone: Substance Abuse and Mental Health Services Administration, U.S. Department of Health & Human Services; 2022 [updated March 29, 2024. Available from: https:\/\/www.samhsa.gov\/substance-use\/treatment\/options\/methadone."},{"key":"1386_CR17","unstructured":"Substance Use and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs Rockville, MD 2015 [Available from: https:\/\/library.samhsa.gov\/product\/federal-guidelines-opioid-treatment-programs-2015\/pep15-fedguideotp."},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"108246","DOI":"10.1016\/j.jsat.2020.108246","volume":"123","author":"D Frank","year":"2021","unstructured":"Frank D. A chance to do it better: methadone maintenance treatment in the age of Covid-19. J Subst Abuse Treat. 2021;123:108246.","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"1386_CR19","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/add.15004","volume":"115","author":"L Durand","year":"2020","unstructured":"Durand L, O\u2019Driscoll D, Boland F, Keenan E, Ryan BK, Barry J, et al. Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study. Addiction. 2020;115(10):1867\u201377.","journal-title":"Addiction"},{"key":"1386_CR20","unstructured":"Bromley L, Kahan M, Regenstreif L, Srivastava A, Wyman J, Dabam F. Methadone treatment for people who use fentanyl: recommendations. Toronto: META: PHI. 2021;24."},{"key":"1386_CR21","unstructured":"Substance Abuse and Mental Health Services Administration, U.S. Department of Health & Human Services. Federal Guidelines for Opioid Treatment Programs (2024) 2024 [Available from: https:\/\/library.samhsa.gov\/product\/federal-guidelines-opioid-treatment-programs-2024\/pep24-02-011."},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"105740","DOI":"10.1016\/j.ypmed.2019.05.028","volume":"128","author":"TJ Stopka","year":"2019","unstructured":"Stopka TJ, Jacque E, Kelso P, Guhn-Knight H, Nolte K, Hoskinson R Jr, et al. The opioid epidemic in rural northern New England: an approach to epidemiologic, policy, and legal surveillance. Prev Med. 2019;128:105740.","journal-title":"Prev Med"},{"key":"1386_CR23","unstructured":"State Unintentional Drug Overdose Reporting System (SUDORS) Final Data. [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2024 December 12[cited]. Available from: https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html."},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2019.03.013","volume":"101","author":"Y Cao","year":"2019","unstructured":"Cao Y, Stewart K, Wish E, Artigiani E, Sorg MH. Determining spatial access to opioid use disorder treatment and emergency medical services in New Hampshire. J Subst Abuse Treat. 2019;101:55\u201366.","journal-title":"J Subst Abuse Treat"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.ypmed.2019.105785","volume":"128","author":"RA Rawson","year":"2019","unstructured":"Rawson RA, Rieckmann T, Cousins S, McCann M, Pearce R. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Prev Med. 2019;128:105785.","journal-title":"Prev Med"},{"key":"1386_CR26","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid Treatment Program Directory [Available from: https:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx."},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"102607","DOI":"10.1016\/j.drugpo.2019.11.015","volume":"85","author":"N Thomas","year":"2020","unstructured":"Thomas N, van de Ven K, Mulrooney KJD. The impact of rurality on opioid-related harms: a systematic review of qualitative research. Int J Drug Policy. 2020;85:102607.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1386_CR28","doi-asserted-by":"publisher","first-page":"E344","DOI":"10.9778\/cmajo.20140089","volume":"3","author":"M Bawor","year":"2015","unstructured":"Bawor M, Dennis BB, Bhalerao A, Plater C, Worster A, Varenbut M, et al. Sex differences in outcomes of methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2015;3(3):E344\u201351.","journal-title":"CMAJ Open"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"100174","DOI":"10.1016\/j.ijnsa.2024.100174","volume":"6","author":"S Rahimi","year":"2024","unstructured":"Rahimi S, Khatooni M. Saturation in qualitative research: an evolutionary concept analysis. Int J Nurs Stud Adv. 2024;6:100174.","journal-title":"Int J Nurs Stud Adv"},{"key":"1386_CR30","doi-asserted-by":"crossref","unstructured":"Swain J. A hybrid approach to thematic analysis in qualitative research: using a practical example. 2018.","DOI":"10.4135\/9781526435477"},{"issue":"6","key":"1386_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"1386_CR32","unstructured":"New Hampshire Department of Health & Human Services. Qualifying Medical Conditions New Hampshire Department of Health & Human Services [Available from: https:\/\/www.dhhs.nh.gov\/programs-services\/population-health\/therapeutic-cannabis\/qualifying-medical-conditions."},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-clinpsy-081423-023518","volume":"21","author":"S Martinez","year":"2025","unstructured":"Martinez S, Ellis JD, Bergeria CL, Huhn AS, Dunn KE. Treating opioid use disorder and opioid withdrawal in the context of fentanyl. Annu Rev Clin Psychol. 2025;21:221\u201349.","journal-title":"Annu Rev Clin Psychol"},{"issue":"5","key":"1386_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jcpt.13114","volume":"45","author":"JV Pergolizzi Jr","year":"2020","unstructured":"Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892\u2013903.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1386_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/ADM.0000000000001473","volume":"19","author":"RC Sherrick","year":"2025","unstructured":"Sherrick RC. Relationship between methadone induction dosing and retention in treatment in opioid treatment programs. J Addict Med. 2025;19(4):446\u20138.","journal-title":"J Addict Med"},{"issue":"12","key":"1386_CR36","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1111\/add.14398","volume":"113","author":"ME Soc\u00edas","year":"2018","unstructured":"Soc\u00edas ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250\u20138.","journal-title":"Addiction"},{"key":"1386_CR37","doi-asserted-by":"publisher","first-page":"101939","DOI":"10.1016\/j.cpr.2020.101939","volume":"82","author":"S Lake","year":"2020","unstructured":"Lake S, St. Pierre M. The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: a systematic review. Clin Psychol Rev. 2020;82:101939.","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"1386_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00406-018-0976-1","volume":"269","author":"AJ Budney","year":"2019","unstructured":"Budney AJ, Sofis MJ, Borodovsky JT. An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):73\u201386.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1386_CR39","doi-asserted-by":"publisher","first-page":"108074","DOI":"10.1016\/j.jsat.2020.108074","volume":"117","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Subst Abuse Treat. 2020;117:108074.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1386_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):88.","journal-title":"Harm Reduct J"},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"209096","DOI":"10.1016\/j.josat.2023.209096","volume":"152","author":"HM Braun","year":"2023","unstructured":"Braun HM, Potee RA. Individualizing methadone treatment with split dosing: an underutilized tool. J Subst Use Addict Treat. 2023;152:209096.","journal-title":"J Subst Use Addict Treat"},{"key":"1386_CR42","unstructured":"National Institute for Health and Care Excellence (NICE). Methadone and buprenorphine for the management of opioid dependence. NICE Guideline TA114; 2007."},{"key":"1386_CR43","doi-asserted-by":"publisher","first-page":"109100","DOI":"10.1016\/j.drugalcdep.2021.109100","volume":"228","author":"EF Madden","year":"2021","unstructured":"Madden EF, Christian BT, Lagisetty PA, Ray BR, Sulzer SH. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1386_CR44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2105\/AJPH.91.5.774","volume":"91","author":"MW Langendam","year":"2001","unstructured":"Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774\u201380.","journal-title":"Am J Public Health"},{"issue":"12","key":"1386_CR45","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","volume":"36","author":"JL Taylor","year":"2021","unstructured":"Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810\u20139.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"1386_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiat. 2014;71(4):359\u201360.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1386_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jrh.12328","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113\u201321.","journal-title":"J Rural Health"},{"key":"1386_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n784","volume":"373","author":"M Buresh","year":"2021","unstructured":"Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784.","journal-title":"BMJ"},{"issue":"9","key":"1386_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/bmjqs-2019-009830","volume":"29","author":"G Elwyn","year":"2020","unstructured":"Elwyn G, Nelson E, Hager A, Price A. Coproduction: when users define quality. BMJ Qual Saf. 2020;29(9):711\u20136.","journal-title":"BMJ Qual Saf"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01386-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:08:05Z","timestamp":1770649685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01386-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01386-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Trustees of Dartmouth College Committee for the Protection of Human Subjects. All participants provided informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}